<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803007</url>
  </required_header>
  <id_info>
    <org_study_id>ACT-CS-002</org_study_id>
    <secondary_id>2018-002855-13</secondary_id>
    <nct_id>NCT03803007</nct_id>
  </id_info>
  <brief_title>Acute Ischemic Stroke Interventional Study</brief_title>
  <acronym>ACTIMIS</acronym>
  <official_title>Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Single Parallel Escalating Dose, Safety &amp; Efficacy Study of ACT017 Used as add-on of SoC Therapy in the 4,5 Hrs Post Onset of Acute Ischemic Stroke Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acticor Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axial Biotech, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>QPS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acticor Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute
      ischemic stroke in addition to best emergency standard of care (including fibrinolysis by
      rtPA with or without added thrombectomy), with a specific focus on hemorrhage, whether
      clinically symptomatic (NIHSS score + 4 points or death, without other explanation), or seen
      (excluding other diagnoses) on 24-hour (hr) CT scan, serious adverse events (SAEs), suspected
      unexpected serious adverse reactions (SUSARs), and medically important events and other
      safety items including biological and immunological tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the escalation dose phase, patients will be unevenly randomized between groups, to end
      with a total of 60 patients, 12 at each dose, providing escalation is complete.

      At the starting level, 8 patients will be administered either ACT017 at the lowest
      pharmacologically active dose of 125 mg (n=4) or the matching placebo (n=4).

      After review by the DSMB of the first 24 hrs clinical data and the 24-hr CT scan, and where
      available MRI images, and providing the opinion is favorable (for criteria, see below, same
      section), the second cohort will be opened and consist of 8 new patients, 4 under the next
      active dose (250 mg), 2 at the initial starting dose (125 mg), and 2 under placebo.

      Depending on next DSMB recommendation, under favorable conditions, the third cohort will be
      opened and patients will be randomized in receiving ACT017 verum 500 mg (n=4), versus 250 mg
      (n=2), 125 mg (n=2) and placebo (n=2), making it a cohort of 10 patients.

      Similarly, still under favorable opinion from DSMB, the fourth cohort will randomize 12 new
      patients between 1000 mg (n=4), 500 mg (n=2), 250 mg (n=2), 125 mg (n=2), or placebo (n=2).

      Once this cohort is administered, the DSMB will provide yet another opinion and, if positive,
      a fifth cohort of 22 patients will be randomized between 1000 mg (n=8), versus 500 mg (n=6),
      250 mg (n=4), 125 mg (n=2), or placebo (n=2).

      This proposed scheme is based on the absence of stopping signal either in dose escalation, or
      in the consolidation phase. It will require a rigorous process to ensure that randomization
      scheme is strictly adhered to, being a multicenter study, so that numbers are precisely those
      expected for each cohort and thus avoid undue consents and screen failures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic intracranial haemorrhages</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of participants experiencing a symptomatic haemorrhage defined by a secondary increase in National Institute Health Stroke Scale score by 4 points or greater, or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of non-symptomatic intracranial haemorrhages</measure>
    <time_frame>24 hours</time_frame>
    <description>Non-symptomatic haemorrhages are those detected by Computerized Tomography scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of National Institute Health Stroke Scale score (7 minimum, 42 maximum), brain lesions and vessel recanalization</measure>
    <time_frame>24 hours</time_frame>
    <description>Absolute change from baseline of National Institute Health Stroke Scale score, change from baseline on brain lesions as assessed by Computerized Tomography scan or Magnetic Resonance Imaging or Magnetic Resonance Angiography, change from baseline on Recanalization as measured by the modified Thrombolysis In Cerebral Infarction score (0 minimum, 3 maximum) on Magnetic Resonance Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of National Institute Health Stroke Scale score (7 minimum, 42 maximum), brain lesions and vessel recanalization</measure>
    <time_frame>24 hours</time_frame>
    <description>Relative (%) change from baseline of National Institute Health Stroke Scale score, change from baseline on brain lesions as assessed by Computerized Tomography scan or Magnetic Resonance Imaging or Magnetic Resonance Angiography, change from baseline on Recanalization as measured by the modified Thrombolysis In Cerebral Infarction score (0 minimum, 3 maximum) on Magnetic Resonance Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of modified Ranking Scale score assessment</measure>
    <time_frame>Day 90</time_frame>
    <description>modified Ranking Scale score (0 minimum and 6 maximum): number of patients with favorable outcome (score 0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of modified Ranking Scale score assessment</measure>
    <time_frame>Day 90</time_frame>
    <description>modified Ranking Scale score (0 minimum and 6 maximum): percentage of patients with favorable outcome (score 0-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on size of infarct zone</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline on size of infarct zone assessed by a central Magnetic Resonance Imaging review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on vital signs</measure>
    <time_frame>6 hours, 24 hours, Day 7, Day 30 and Day 90</time_frame>
    <description>Change from baseline on systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on vital signs</measure>
    <time_frame>6 hours, 24 hours, Day 7, Day 30 and Day 90</time_frame>
    <description>Change from baseline on heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on clinical laboratory assessments</measure>
    <time_frame>Day 90</time_frame>
    <description>Change from baseline on plasma haemoglobin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on clinical laboratory assessments</measure>
    <time_frame>Day 90</time_frame>
    <description>Change from baseline on platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on clinical laboratory assessments</measure>
    <time_frame>Day 90</time_frame>
    <description>Change from baseline on serum glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on clinical laboratory assessments</measure>
    <time_frame>Day 90</time_frame>
    <description>Change from baseline on serum creatinine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on ElectroCardioGram (ECG)</measure>
    <time_frame>24 hours and Day 90</time_frame>
    <description>Change from baseline on 12-lead ElectroCardioGram (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of anti-ACT017 antibodies (ADA)</measure>
    <time_frame>Day 30 and Day 90</time_frame>
    <description>To assess evidence of anti-ACT017 antibodies (ADA) as a possible to ACT017 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics on ACT017 plasma concentration</measure>
    <time_frame>30 minutes, 9 hours and 24 hours</time_frame>
    <description>Change from baseline on ACT017 plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous ACT017 125 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ACT017 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous ACT017 250 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ACT017 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous ACT017 500 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ACT017 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous ACT017 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ACT017 125 mg</intervention_name>
    <description>Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms</description>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Thrombolysis by rtPA +/- thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ACT017 250 mg</intervention_name>
    <description>Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms</description>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 250 mg</arm_group_label>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Thrombolysis by rtPA +/- thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ACT017 500 mg</intervention_name>
    <description>Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms</description>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 250 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 500 mg</arm_group_label>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Thrombolysis by rtPA +/- thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ACT017 1000 mg</intervention_name>
    <description>Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms</description>
    <arm_group_label>Intravenous ACT017 1000 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 250 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 500 mg</arm_group_label>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Thrombolysis by rtPA +/- thrombectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous Placebo</intervention_name>
    <description>Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms</description>
    <arm_group_label>Intravenous ACT017 1000 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 125 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 250 mg</arm_group_label>
    <arm_group_label>Intravenous ACT017 500 mg</arm_group_label>
    <arm_group_label>Intravenous Placebo</arm_group_label>
    <other_name>Thrombolysis by rtPA +/- thrombectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female patients ≥ 18 years (i.e., at least 18 years old at time of
             randomization);

          -  Presenting with an acute ischemic stroke confirmed by imaging showing intra-cranial
             anterior circulation large vessel occlusion, including distal segments (M3), with a
             known time of onset, or when unknown the last time seen well that is inferior or as a
             maximum equal to 4.5 hrs when the diagnosis is ascertained and sufficient to allow the
             test treatment to be administered in this time-window;

          -  Who are eligible to thrombolysis treatment with rtPA;

          -  Who may undergo mechanical thrombectomy if eligible;

        Exclusion Criteria:

          -  Coma, and/or NIHSS &gt;25;

          -  Stroke of hemorrhagic origin;

          -  Prior ischemic stroke within the past 3 months with mRS pre-stroke known to be ≥2;

          -  Contra-indication to thrombolysis with rtPA:

          -  Patients receiving anti-coagulants with the exception of heparin intake with a maximum
             dose of 50 IU/kg exclusively during the mechanical thrombectomy procedure;

          -  Systolic blood pressure ≥185 mm Hg;

          -  Diastolic blood pressure ≥110 mm Hg;

          -  Glucose &gt;200 mg/dL or &lt;50 mg/dL;

          -  Platelets &lt;100 × 103/μL;

          -  aPTT &gt;39 s;

          -  Prior hemorrhagic stroke.

          -  Need for carotid stenting together with a dual anti-platelet treatment;

          -  Concurrent anti-thrombotic treatment including anti-platelet agents, NSAIDs, and more
             generally with other medicines likely to interfere with hemostasis;

          -  Hemorrhagic diathesis;

          -  Known impaired renal function or serum creatinine &gt;2X ULN (110 micromol/l or 1.2
             mg/dl) at screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Comenducci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acticor Biotech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Comenducci, MD</last_name>
    <phone>+33631003997</phone>
    <email>andrea.comenducci@acticor-biotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yannick Pletan, MD</last_name>
    <phone>+33685946370</phone>
    <email>yannick.pletan@acticor-biotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Acticor Biotech</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.tandfonline.com/doi/full/10.1080/19420862.2017.1336592</url>
    <description>Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S1871678418300529?via%3Dihub</url>
    <description>Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemorrhages</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Thrombectomy</keyword>
  <keyword>Anti-platelet</keyword>
  <keyword>Dose-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

